Tamoxifen chemoprophylaxis is a cost-effective therapy that successfully reduces breast cancer incidence among women younger than 55 years, even after the drug is discontinued, according to a study published online March 14 in Cancer.
MONDAY, March 14 (HealthDay News) -- Tamoxifen chemoprophylaxis is a cost-effective therapy that successfully reduces breast cancer incidence among women younger than 55 years, even after the drug is discontinued, according to a study published online March 14 in Cancer.
Joyce Noah-Vanhoucke, Ph.D., of Archimedes Inc. in San Francisco, and colleagues investigated the cost-effectiveness of tamoxifen for chemoprevention of breast cancer. In a virtual trial, they compared five years of tamoxifen treatment with no treatment for lifetime follow-up. A model of breast cancer and health care processes was used to simulate a postmenopausal population younger than 55 years. The model was based on a meta-analysis of four chemoprevention trials that indicated the risk of breast cancer was reduced for 10 years after ending treatment. Data on disease incidence, survival, quality-adjusted life year (QALY) utility weights, and costs were derived for multiple five-year breast cancer risk thresholds and risk groups.
The researchers found that, compared to no treatment, tamoxifen therapy was cost-saving when populations at higher risk were targeted (five-year risk, ≥1.66 percent), and the benefits of therapy compensated for its side-effect profile. Compared with no treatment, tamoxifen treatment saved 29 QALYs in 1,000 postmenopausal women younger than 55 years, with an added cost of $333,000 over the population's lifetime. The results were consistent even after inclusion of quality-adjusted utilities, which are associated with tamoxifen-induced menopausal symptoms.
"Tamoxifen chemoprophylaxis for postmenopausal women aged <55 years is a cost-effective health policy that reduces breast cancer incidence and improves life expectancy," the authors write.
AbstractFull Text (subscription or payment may be required)
Eribulin Improves Survival in Metastatic Breast CancerTiming of Hormone Therapy Influences Breast Cancer RiskFibrocystic Breast Disease